China In-Depth Reports
Discover the Future of Ulcerative Colitis Treatment
Key market forecasts in Ulcerative Colitis:
- Forecast: 10-year, annualized, drug-level sales and patient shares of key ulcerative colitis therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions.
- Epidemiology: Total diagnosed prevalent cases of UC in both urban and rural China. Clinically and market relevant drug-treatable populations.
- Additional content: Downloadable Excel files containing detailed forecast assumptions and visual outputs.
Request more information
What are China in-depth reports?
China in-depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
- Gauge the commercial outlook and impact of key market events.
Expert insights on Ulcerative Colitis
Built on expert knowledge and rigorous research
- Qualitative and quantitative insights driven by 5 thought leader interviews and surveys with 50 gastroenterologists in China
- Diagnosed prevalence of ulcerative colitis in urban versus rural China, clinically relevant and market-relevant drug-treatable populations
- 10-year, annualized, drug-level sales and patient share of key ulcerative colitis therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions
- Coverage of key current and late-phase emerging therapies
- Integrated tool to input customized forecast assumptions (e.g., launch date, price)
The Ulcerative Colitis China In-Depth report provides comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.
Key questions answered:
- What is the size of China’s diagnosed UC population, and how will drug-treatment rates change over the forecast period?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of UC in China?
- What are the key market access considerations for branded therapies in the UC pipeline in China? What sales / uptake could they secure?
- What are the key drivers of and constraints in China’s UC therapy market, and how will the market evolve over the forecast period?
Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.